Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, Nov. 06, 2026 (ZM NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it has arranged a non-brokered private placement offering of 1,058,823 common shares priced at $0.85 per common share (the “Common Shares”), for gross proceeds of $900,000 CAD (the “Offering”).

The proceeds of the Offering will be used by Arch to begin onboarding clinical sites in the U.S. for the Company’s Phase II trial for LSALT peptide targeting cardiac surgery-associated acute kidney injury, to accelerate pre-clinical studies for the Company’s IL-32 chronic kidney disease program, to market the Company to a larger financial and industry audience, and for general working capital to be used for operating expenses.

The Offering will settle on or about November 12, 2026, and is subject to certain conditions including, but not limited to, the receipt of applicable regulatory approvals, including conditional and final approvals from the TSX Venture Exchange, as well as the satisfaction of customary closing conditions.

The Offering will involve the issuance of 729,411 of the Common Shares to an officer of the Company and therefore a “related party” (as such term is defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101“)) and therefore constitutes a related party transaction under MI 61-101. This transaction is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 pursuant to sections 5.5(a) and 5.7(1)(a) of MI 61-101, as the fair market value of the Common Shares distributed and the consideration received from the related party in the Private Placement does not exceed 25% of the Company’s market capitalization.

All Common Shares issued in connection with the Offering will be subject to a hold period of four months and one day from the closing date. There are finders’ fees expected to be paid in connection with one non-related party subscriber to the Offering. The final amount of the finder’s fees will be confirmed on the settlement day.

There is no material fact or material change about the Company that has not been generally disclosed.

About Arch Biopartners

Arch Biopartners Inc. is a therapeutic biotechnology company developing on-target drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The Company is advancing an integrated program that includes new treatments targeting inflammation- and toxin-related kidney injury.

Arch’s development pipeline includes:

• LSALT peptide: in a Phase II trial targeting cardiac surgery-associated AKI.
• Cilastatin: a repurposed drug in a Phase II trial targeting toxin-induced AKI.
• CKD Platform: next-generation therapeutics targeting chronic kidney disease.

These assets represent distinct, mechanism-based approaches to protecting the kidney from common causes of acute and chronic damage. Chronic kidney disease affects more than 800 million people worldwide¹, while acute kidney injury adds a further significant burden. Together, Arch’s programs target unmet needs across both acute and chronic kidney disease.

Both Phase II programs are currently enrolling patients at Canadian clinical sites, with an additional Canadian site in development and a U.S. expansion of the CS-AKI trial underway.

For more details about the Company’s science and ongoing clinical trials, please visit www.archbiopartners.com/our-science

Follow Arch on LinkedIn, Bluesky, and X (formerly Twitter) for company updates and scientific content.

The Company has 67,933,289 common shares outstanding.

For more information, please contact:

Aaron Benson
Director of Communications
Arch Biopartners Inc.
647-428-7031

Send a message or subscribe for updates at www.archbiopartners.com/contact-us

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable Canadian securities laws, including statements concerning the proposed Offering, the anticipated number and price of Common Shares to be issued, expected gross proceeds, participation by insiders, the anticipated closing date, the intended use of proceeds and the receipt of applicable regulatory approvals. This release also contains forward-looking statements regarding expectations of the Company’s future performance, liquidity, and capital resources, as well as the ongoing development of its drug candidates targeting chronic kidney disease and the dipeptidase-1 (DPEP1) pathway, including the outcomes of its clinical trials relating to LSALT peptide (Metablok) and cilastatin, the successful commercialization and marketing of its drug candidates, whether the Company will receive, and the timing and costs of obtaining, regulatory approvals in Canada, the United States, Europe, and other countries, its ability to raise capital to fund its business plans, the efficacy of its drug candidates compared to the drug candidates developed by competitors, its ability to retain and attract key management personnel, and the breadth of, and its ability to protect, its intellectual property portfolio. These statements are based on management’s current expectations and beliefs, including certain factors and assumptions, as described in the Company’s most recent annual audited financial statements and related management’s discussion and analysis under the heading “Business Risks and Uncertainties”. As a result of these risks and uncertainties, or other unknown risks and uncertainties, actual results may differ materially from those contained in any forward-looking statements. There can be no assurance that the Offering will be completed on the terms announced or at all, or that the required regulatory approvals will be obtained. The words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company undertakes no obligation to update forward-looking statements, except as required by law. Additional information relating to Arch Biopartners Inc., including the Company’s most recent annual audited financial statements, is available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (“SEDAR+”) website at www.sedarplus.ca.

References:

1. Mark, Patrick B et al. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet, 2025;406(10518), 2461 – 2482. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01853-7/fulltext

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Publication Partner: ZM Newswire – Powered By Zeest Media